drugset / Trial / NCT06740890

Exercise and Olanzapine-samidorphan

NCT06740890

Phase 4 Recruiting 30 enrolled New York State Psychiatric Institute
NaSingle-groupOpen-labelTreatment

Summary

This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.

Timeline

Start
2025-06-26
Primary completion
2027-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule
Subject Samidorphan Small molecule 10 mg